Sido Muncul (SIDO) Distributes Rp 647.57 Billion Interim Dividend, Backed by Strong Profit Growth
Key Takeaways
|
JAKARTA, investortrust.id — PT Industri Jamu dan Farmasi Sido Muncul Tbk, or Sido Muncul (SIDO), has announced an interim dividend for fiscal year 2025 worth Rp 647.57 billion, following the approval of the board of commissioners on Wednesday, Oct 29, 2025.
In its filing to the Indonesia Stock Exchange on Friday, Oct 31, 2025, the herbal medicine producer confirmed that shareholders would receive Rp 22 per share. The dividend does not constitute any form of equity securities and cannot be converted into shares.
The payout reflects Sido Muncul’s solid profitability as of Sept 30, 2025, with net profit attributable to the parent entity reaching Rp 818.54 billion, retained earnings of Rp 1.51 trillion, and total equity standing at Rp 3.41 trillion.
The company set the ex-dividend dates as follows: the regular and negotiation market on Nov 10, 2025; the cash market on Nov 12, 2025; and the payment date on Nov 20, 2025.
Through the first nine months of 2025, Sido Muncul recorded Rp 2.73 trillion in sales, higher than Rp 2.63 trillion in the same period last year. The stronger revenue lifted gross profit to Rp 1.55 trillion from Rp 1.49 trillion in 2024. Operating profit reached Rp 1.03 trillion, up from Rp 969.09 billion a year earlier.
Profit before tax stood at Rp 1.05 trillion, and after accounting for Rp 234.20 billion in income tax, net profit attributable to shareholders amounted to Rp 818.54 billion, compared with Rp 778.12 billion in 2024.
Valuation
Based on InvestingPro data, Sido Muncul shares were priced at Rp 570 at the close, up 0.88% on the day. The 52-week range stood between Rp 480 and Rp 630. The average fair value estimated by analysts was Rp 695.33 per share, implying a 22% upside potential from the current price. Analyst target consensus placed fair value around Rp 594.62, while InvestingPro models indicated a value range of Rp 454 to Rp 998 per share.
Financial health indicators remained solid, with high cash flow health (score 4/5), profitability (4/5), and a strong balance sheet holding more cash than debt. The company’s valuation metrics also showed low earnings multiples relative to peers, reinforcing its position as one of Indonesia’s strongest consumer staples firms.

